FTSE 100 today: Index, pound edge higher; StanChart, Revolution Beauty jump
Alfred Sandrock, the President and CEO of Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotech company with a market capitalization of $225 million and strong financial health according to InvestingPro, recently sold shares of the company, according to a Form 4 filing with the Securities and Exchange Commission. On February 20, Sandrock sold 11,702 shares of common stock at an average price of $4.24 per share, totaling $49,616. The sale occurred with the stock trading near its 52-week low and showing oversold conditions based on technical indicators. Following this transaction, Sandrock holds 296,816 shares directly. InvestingPro analysis shows 8 additional key insights about VYGR’s current market position.
In addition to the sale, Sandrock acquired 145,000 restricted stock units on February 21, 2025, at no cost, as part of Voyager Therapeutics’ 2015 Stock Option and Incentive Plan. These units vest over a three-year period. Sandrock also received stock options for 290,000 shares, which will vest over four years, further strengthening his position in the company, which maintains a healthy balance sheet with a current ratio of 8.45 and trades at a P/E ratio of 8.87.
In other recent news, Voyager Therapeutics announced a delay in its investigational new drug (IND) application for its ALS gene therapy candidate, VY9323, initially expected in mid-2025. The company is reassessing its approach due to off-target effects in non-human primate studies and will explore alternative payloads. Despite this setback, Voyager’s other gene therapy programs, including those for GBA1 Parkinson’s disease and Friedreich’s ataxia, remain on schedule, with IND filings anticipated in 2025. Analysts from H.C. Wainwright and Citi have maintained a positive outlook on Voyager Therapeutics, with H.C. Wainwright setting a $30 price target and Citi assigning a $12 target, both highlighting the company’s strong gene therapy pipeline. Voyager’s financial outlook appears stable, with cash reserves projected to last until mid-2027. The company’s proprietary TRACER platform continues to be a focal point, promising advancements in CNS gene therapy. Collaborative efforts with Neurocrine (NASDAQ:NBIX) Biosciences are ongoing, with plans to file additional IND applications. Voyager’s leadership remains optimistic about addressing unmet medical needs in neurological disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.